What is PharmCADD?
Founded in 2019 and headquartered in Busan, South Korea, PharmCADD is a pioneering company leveraging Artificial Intelligence (AI) and physics-based design to accelerate the discovery and development of novel therapeutics. The company's core mission is to streamline the path for creating new treatments for various diseases more efficiently. PharmCADD operates within the rapidly evolving intersection of biotechnology and artificial intelligence, a field attracting substantial investment due to its potential to revolutionize healthcare.
How much funding has PharmCADD raised?
PharmCADD has raised a total of $22.5M across 2 funding rounds:
Series A
$6.5M
Series B
$16M
Series A (2020): $6.5M with participation from KTB Network, Venture capital, and Daily Partners
Series B (2021): $16M, investors not publicly disclosed
Key Investors in PharmCADD
KTB Network
KTB Network is a venture capital firm known for investing in technology and innovation across various sectors, likely focusing on early to growth-stage companies.
Daily Partners
Daily Partners appears to be an investment firm that provides strategic backing, potentially with a focus on technology and growth-oriented businesses.
What's next for PharmCADD?
The substantial enterprise-level funding PharmCADD has attracted positions it for significant scaling and further research and development. This capital injection is expected to fuel advancements in its AI-driven drug design platform, potentially expanding its therapeutic pipeline and market reach. The company's strategic focus on de-novo drug discovery, combined with its technological capabilities, suggests a trajectory aimed at addressing unmet medical needs and capturing a larger share of the pharmaceutical innovation landscape. Future growth will likely involve further platform refinement, strategic partnerships, and clinical development milestones.
See full PharmCADD company page
